<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01995448</url>
  </required_header>
  <id_info>
    <org_study_id>I11020 SEPTIFLUX 2</org_study_id>
    <nct_id>NCT01995448</nct_id>
  </id_info>
  <brief_title>Prognostic Interest of Leucocyte Immunophenotyping During the Acute Phase of Sepsis</brief_title>
  <acronym>SEPTIFLUX2</acronym>
  <official_title>Prognostic Interest of Leucocyte Immunophenotyping Using Multiparameter 8-color Flow Cytometry During the Acute Phase of Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Septic shock is still a major cause of death in ICU. Sepsis diagnosis is linked with many
      clinical, hemodynamic and biological criteria which have a low sensitivity and specificity if
      they are considered separately. The extensive experimental data which have been published
      contrast with the hematological data collected by the physician at patient's bedside
      especially regarding neutrophils and platelets levels. When there is no obvious clinical
      sign, a biological tool reflecting the patient's immune status could be useful to understand
      the physiopathology of Sepsis and to predict the progression of the disease in the patient.
      On the long-term it could also help to define management strategies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>expression of the marker CD10</measure>
    <time_frame>28 days</time_frame>
    <description>Expression of CD10 on granulocytes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progession of SOFA score</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of the marker CD16</measure>
    <time_frame>28 days</time_frame>
    <description>Expression of CD16 on granulocytes and on monocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of the marker CD24</measure>
    <time_frame>28 days</time_frame>
    <description>Expression of CD24 on granulocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of the marker CD64</measure>
    <time_frame>28 days</time_frame>
    <description>Expression of CD64 on granulocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of the marker CD14</measure>
    <time_frame>28 days</time_frame>
    <description>Expression of CD14 on monocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of the marker CD3</measure>
    <time_frame>28 days</time_frame>
    <description>Expression of CD3 on T lymphocytes.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1000</enrollment>
  <condition>Sepsis With Acute Organ Dysfunction</condition>
  <arm_group>
    <arm_group_label>SEPSIS Blood test</arm_group_label>
    <description>Patient with two criteria of systemic inflammatory response syndrome and a progressive infection which is clinically or microbiologically documented.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>Residue of blood further to NFS.</description>
    <arm_group_label>SEPSIS Blood test</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Residue of blood further to NFS.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with two criteria of systemic inflammatory response syndrome and a progressive
        infection which is clinically or microbiologically documented
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient older than 18 years old

          -  Patient with two criteria of systemic inflammatory response syndrome and a progressive
             infection which is clinically or microbiologically documented

        Exclusion Criteria:

          -  Pregnancy,

          -  progressive solid cancer,

          -  HIV infection,

          -  history of blood or inflammatory disease,

          -  long-term immunosuppressive treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno FRANCOIS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU LIMOGES</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Bordeaux - Service Réanimation Médicale</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Henri MONDOR - Service Réanimation</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dijon - Service Réanimation Médicale</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Limoges - Service de réanimation polyvalente</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Orléans - Service de Réanimation Médicale</name>
      <address>
        <city>Orleans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin - service de Réanimation</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers - Service Réanimation</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes - service de Réanimation</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Tours - Service de Réanimation</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2013</study_first_submitted>
  <study_first_submitted_qc>November 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2013</study_first_posted>
  <last_update_submitted>February 23, 2016</last_update_submitted>
  <last_update_submitted_qc>February 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>The acute phase of Sepsis</keyword>
  <keyword>multiparameter 8-color flow cytometry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

